JP2017537081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537081A5 JP2017537081A5 JP2017524451A JP2017524451A JP2017537081A5 JP 2017537081 A5 JP2017537081 A5 JP 2017537081A5 JP 2017524451 A JP2017524451 A JP 2017524451A JP 2017524451 A JP2017524451 A JP 2017524451A JP 2017537081 A5 JP2017537081 A5 JP 2017537081A5
- Authority
- JP
- Japan
- Prior art keywords
- rapamycin
- less
- composition
- amount
- carrier material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 31
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 30
- 229960002930 sirolimus Drugs 0.000 claims 30
- 230000002209 hydrophobic effect Effects 0.000 claims 17
- 229920000728 polyester Polymers 0.000 claims 17
- 239000012876 carrier material Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 14
- 239000002539 nanocarrier Substances 0.000 claims 13
- 239000002736 nonionic surfactant Substances 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 150000002191 fatty alcohols Chemical class 0.000 claims 4
- 238000001914 filtration Methods 0.000 claims 4
- -1 sorbitan ester Chemical class 0.000 claims 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 101000634900 Homo sapiens Transcriptional-regulating factor 1 Proteins 0.000 claims 2
- 241001506137 Rapa Species 0.000 claims 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims 2
- 102100029446 Transcriptional-regulating factor 1 Human genes 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 2
- 229920001610 polycaprolactone Polymers 0.000 claims 2
- 239000004632 polycaprolactone Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims 1
- MGYUQZIGNZFZJS-KTKRTIGZSA-N 2-[2-[(z)-octadec-9-enoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCO MGYUQZIGNZFZJS-KTKRTIGZSA-N 0.000 claims 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 229920002415 Pluronic P-123 Polymers 0.000 claims 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 claims 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- 229940055577 oleyl alcohol Drugs 0.000 claims 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001440 poly(ε-caprolactone)-block-poly(ethylene glycol) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000000935 solvent evaporation Methods 0.000 claims 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022139392A JP2022173236A (ja) | 2014-11-05 | 2022-09-01 | 安定した過飽和状態でラパマイシンをもつ合成ナノキャリアに関する方法および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075864P | 2014-11-05 | 2014-11-05 | |
| US201462075866P | 2014-11-05 | 2014-11-05 | |
| US62/075,866 | 2014-11-05 | ||
| US62/075,864 | 2014-11-05 | ||
| PCT/US2015/059350 WO2016073799A1 (en) | 2014-11-05 | 2015-11-05 | Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022139392A Division JP2022173236A (ja) | 2014-11-05 | 2022-09-01 | 安定した過飽和状態でラパマイシンをもつ合成ナノキャリアに関する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537081A JP2017537081A (ja) | 2017-12-14 |
| JP2017537081A5 true JP2017537081A5 (https=) | 2018-12-13 |
| JP7218089B2 JP7218089B2 (ja) | 2023-02-06 |
Family
ID=54697646
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017524450A Active JP6912377B2 (ja) | 2014-11-05 | 2015-11-05 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
| JP2017524451A Active JP7218089B2 (ja) | 2014-11-05 | 2015-11-05 | 安定した過飽和状態でラパマイシンをもつ合成ナノキャリアに関する方法および組成物 |
| JP2021080003A Active JP7827412B2 (ja) | 2014-11-05 | 2021-05-10 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
| JP2022139392A Pending JP2022173236A (ja) | 2014-11-05 | 2022-09-01 | 安定した過飽和状態でラパマイシンをもつ合成ナノキャリアに関する方法および組成物 |
| JP2023109379A Pending JP2023169893A (ja) | 2014-11-05 | 2023-07-03 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017524450A Active JP6912377B2 (ja) | 2014-11-05 | 2015-11-05 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021080003A Active JP7827412B2 (ja) | 2014-11-05 | 2021-05-10 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
| JP2022139392A Pending JP2022173236A (ja) | 2014-11-05 | 2022-09-01 | 安定した過飽和状態でラパマイシンをもつ合成ナノキャリアに関する方法および組成物 |
| JP2023109379A Pending JP2023169893A (ja) | 2014-11-05 | 2023-07-03 | ラパログを含む合成ナノキャリアの生産における低ｈｌｂ界面活性剤の使用に関連した方法および組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20160128986A1 (https=) |
| EP (6) | EP4356910A3 (https=) |
| JP (5) | JP6912377B2 (https=) |
| KR (2) | KR102601922B1 (https=) |
| CN (5) | CN107072964A (https=) |
| AU (4) | AU2015342969B2 (https=) |
| BR (3) | BR122021025344B1 (https=) |
| CA (2) | CA2966852C (https=) |
| CY (1) | CY1124418T1 (https=) |
| DK (4) | DK3215192T3 (https=) |
| EA (2) | EA201790977A1 (https=) |
| ES (4) | ES2977259T3 (https=) |
| FI (2) | FI3834823T3 (https=) |
| HR (1) | HRP20210098T1 (https=) |
| HU (4) | HUE054894T2 (https=) |
| IL (7) | IL296246A (https=) |
| LT (1) | LT3215133T (https=) |
| MX (4) | MX386982B (https=) |
| PL (1) | PL3215133T3 (https=) |
| PT (1) | PT3215133T (https=) |
| RS (1) | RS61359B1 (https=) |
| SI (1) | SI3215133T1 (https=) |
| WO (2) | WO2016073799A1 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2762653A1 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
| AU2011258165B2 (en) | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| KR20140041505A (ko) | 2011-04-29 | 2014-04-04 | 셀렉타 바이오사이언시즈, 인크. | 조절 b 세포 유도를 위한 관용원성 합성 나노운반체 |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| HUE052599T2 (hu) | 2013-05-03 | 2021-05-28 | Selecta Biosciences Inc | CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények |
| WO2015025538A1 (ja) * | 2013-08-20 | 2015-02-26 | サンノプコ株式会社 | バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法 |
| AU2015311704B2 (en) | 2014-09-07 | 2021-12-09 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses |
| JP6774591B2 (ja) * | 2015-02-17 | 2020-10-28 | サンノプコ株式会社 | バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法 |
| WO2016176462A1 (en) | 2015-04-28 | 2016-11-03 | University Of Central Florida Foundation, Inc. | Methods and compositions for theranostic nanoparticles |
| ES2986077T3 (es) | 2016-03-11 | 2024-11-08 | Cartesian Therapeutics Inc | Formulaciones y dosis de uricasa pegilada |
| KR102341902B1 (ko) * | 2016-09-09 | 2021-12-21 | 카오카부시키가이샤 | 디카르복실산 결정 및 그 제조 방법 |
| JP2019533718A (ja) | 2016-09-27 | 2019-11-21 | セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | がんの処置における使用のための組換え免疫毒素 |
| US20180193482A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
| WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| AU2018347583A1 (en) | 2017-10-13 | 2020-05-21 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector IgM responses |
| JP2022518504A (ja) * | 2019-01-24 | 2022-03-15 | ジェネレーション バイオ カンパニー | 閉端ｄｎａ（ｃｅｄｎａ）ならびに遺伝子療法または核酸療法に関連する免疫応答を低減させる方法における使用 |
| CN114126666A (zh) | 2019-04-28 | 2022-03-01 | 西莱克塔生物科技公司 | 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法 |
| CA3141863A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| CN114207440A (zh) | 2019-06-04 | 2022-03-18 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
| EP4048269A1 (en) | 2019-10-21 | 2022-08-31 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
| US20210187081A1 (en) | 2019-11-08 | 2021-06-24 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
| KR20220146559A (ko) | 2020-02-26 | 2022-11-01 | 셀렉타 바이오사이언시즈, 인크. | 면역억제제를 포함하는 합성 나노담체를 사용하는 방법 및 조성물 |
| AU2021236234A1 (en) * | 2020-03-11 | 2022-10-06 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
| EP4135693A1 (en) * | 2020-04-14 | 2023-02-22 | Selecta Biosciences, Inc. | Methods and compositions for inducing autophagy |
| IL302539A (en) | 2020-11-04 | 2023-07-01 | Selecta Biosciences Inc | Compositions for reducing immune responses against immunoglobulin proteases |
| EP4274571A1 (en) | 2021-01-05 | 2023-11-15 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| KR102304785B1 (ko) | 2021-03-26 | 2021-09-24 | (주)진성티앤피 | 정밀광학기기의 부품 제조 방법 |
| EP4319747A1 (en) | 2021-04-09 | 2024-02-14 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| US20230140196A1 (en) | 2021-10-12 | 2023-05-04 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| CA3237037A1 (en) | 2021-11-14 | 2023-05-19 | Cartesian Therapeutics, Inc. | Multiple dosing with viral vectors |
| US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| WO2023172628A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| US20230381277A1 (en) | 2022-04-08 | 2023-11-30 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| CN120813689A (zh) | 2022-08-11 | 2025-10-17 | 笛卡尔疗法股份有限公司 | 与免疫球蛋白蛋白酶及其融合体相关的组合物和方法 |
| WO2024107889A1 (en) | 2022-11-15 | 2024-05-23 | Selecta Biosciences, Inc. | Compositions and methods for treating primary biliary cholangitis |
| WO2024229432A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| WO2024229380A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases |
| WO2024229370A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Compositions and methods for treating gvhd |
| WO2024229350A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes |
| TWI877967B (zh) * | 2023-12-28 | 2025-03-21 | 訊聯生物科技股份有限公司 | 包含小分子核糖核酸及奈米載體之組合物、包含其的醫藥組成物及其用途 |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| US5759830A (en) | 1986-11-20 | 1998-06-02 | Massachusetts Institute Of Technology | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US7288266B2 (en) | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| JP2002521423A (ja) | 1998-07-31 | 2002-07-16 | コリア インスティチュート オブ サイエンス アンド テクノロージ | 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子 |
| JP4526708B2 (ja) * | 1998-09-01 | 2010-08-18 | メリオン リサーチ スリー リミテッド | 細胞を媒介した免疫応答を誘導する方法及びそのための非経口ワクチン製剤 |
| JP4751556B2 (ja) | 2000-02-28 | 2011-08-17 | ジーンシーグス， インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
| US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| AU2003270102B2 (en) | 2002-08-23 | 2008-10-02 | Medigene Ag | Non-vesicular cationic lipid formulations |
| CN1886100A (zh) * | 2003-11-14 | 2006-12-27 | 阿尔萨公司 | 基于表面活性剂的凝胶作为可注射的持续药物递送载体 |
| US20050260260A1 (en) | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
| AU2006284657B2 (en) * | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US8414910B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| EP2630966B1 (en) | 2007-10-12 | 2017-04-19 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| JP2012501965A (ja) * | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| US8613951B2 (en) * | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| US20100216804A1 (en) * | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
| KR101267813B1 (ko) | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| AU2011303849A1 (en) * | 2010-09-14 | 2013-04-04 | Nanologica Ab | Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients |
| WO2012059936A1 (en) * | 2010-11-03 | 2012-05-10 | Padma Venkitachalam Devarajan | Pharmaceutical compositions for colloidal drug delivery |
| KR20140041505A (ko) * | 2011-04-29 | 2014-04-04 | 셀렉타 바이오사이언시즈, 인크. | 조절 b 세포 유도를 위한 관용원성 합성 나노운반체 |
| CN102793674B (zh) * | 2011-05-26 | 2014-11-26 | 澳门科技大学 | 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用 |
| JP2014532071A (ja) | 2011-10-14 | 2014-12-04 | エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ | カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法 |
| TWI439288B (zh) * | 2012-10-05 | 2014-06-01 | Univ China Medical | 藥用載體及其製備方法與用途 |
| CN102871966B (zh) * | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
-
2015
- 2015-11-05 ES ES21156943T patent/ES2977259T3/es active Active
- 2015-11-05 PL PL15798601T patent/PL3215133T3/pl unknown
- 2015-11-05 EA EA201790977A patent/EA201790977A1/ru unknown
- 2015-11-05 FI FIEP20204014.3T patent/FI3834823T3/fi active
- 2015-11-05 EP EP23220845.4A patent/EP4356910A3/en not_active Withdrawn
- 2015-11-05 EP EP15798601.9A patent/EP3215133B1/en active Active
- 2015-11-05 HU HUE15857076A patent/HUE054894T2/hu unknown
- 2015-11-05 JP JP2017524450A patent/JP6912377B2/ja active Active
- 2015-11-05 EP EP20204014.3A patent/EP3834823B1/en active Active
- 2015-11-05 MX MX2017005904A patent/MX386982B/es unknown
- 2015-11-05 MX MX2017005903A patent/MX383295B/es unknown
- 2015-11-05 DK DK15857076.2T patent/DK3215192T3/da active
- 2015-11-05 ES ES15857076T patent/ES2865375T3/es active Active
- 2015-11-05 AU AU2015342969A patent/AU2015342969B2/en active Active
- 2015-11-05 SI SI201531494T patent/SI3215133T1/sl unknown
- 2015-11-05 CN CN201580059855.4A patent/CN107072964A/zh active Pending
- 2015-11-05 US US14/934,132 patent/US20160128986A1/en active Pending
- 2015-11-05 PT PT157986019T patent/PT3215133T/pt unknown
- 2015-11-05 DK DK20204014.3T patent/DK3834823T3/da active
- 2015-11-05 WO PCT/US2015/059350 patent/WO2016073799A1/en not_active Ceased
- 2015-11-05 CA CA2966852A patent/CA2966852C/en active Active
- 2015-11-05 BR BR122021025344-7A patent/BR122021025344B1/pt active IP Right Grant
- 2015-11-05 HU HUE21156943A patent/HUE067697T2/hu unknown
- 2015-11-05 HU HUE20204014A patent/HUE066099T2/hu unknown
- 2015-11-05 HU HUE15798601A patent/HUE053094T2/hu unknown
- 2015-11-05 CN CN201580060789.2A patent/CN107072965B/zh active Active
- 2015-11-05 CA CA2966850A patent/CA2966850C/en active Active
- 2015-11-05 LT LTEP15798601.9T patent/LT3215133T/lt unknown
- 2015-11-05 US US14/934,135 patent/US20160128987A1/en not_active Abandoned
- 2015-11-05 BR BR112017008499-6A patent/BR112017008499B1/pt active IP Right Grant
- 2015-11-05 CN CN202110403075.4A patent/CN113244191A/zh active Pending
- 2015-11-05 KR KR1020177014831A patent/KR102601922B1/ko active Active
- 2015-11-05 IL IL296246A patent/IL296246A/en unknown
- 2015-11-05 EP EP21156943.9A patent/EP3906918B1/en active Active
- 2015-11-05 RS RS20210097A patent/RS61359B1/sr unknown
- 2015-11-05 EP EP23220853.8A patent/EP4360633A3/en not_active Withdrawn
- 2015-11-05 ES ES15798601T patent/ES2846809T3/es active Active
- 2015-11-05 IL IL295292A patent/IL295292B2/en unknown
- 2015-11-05 FI FIEP21156943.9T patent/FI3906918T3/fi active
- 2015-11-05 EA EA201790978A patent/EA201790978A1/ru unknown
- 2015-11-05 DK DK21156943.9T patent/DK3906918T3/da active
- 2015-11-05 CN CN202210754573.8A patent/CN115212187A/zh active Pending
- 2015-11-05 IL IL283699A patent/IL283699B/en unknown
- 2015-11-05 WO PCT/US2015/059349 patent/WO2016073798A1/en not_active Ceased
- 2015-11-05 EP EP15857076.2A patent/EP3215192B1/en active Active
- 2015-11-05 CN CN202210754468.4A patent/CN115212186A/zh active Pending
- 2015-11-05 HR HRP20210098TT patent/HRP20210098T1/hr unknown
- 2015-11-05 DK DK15798601.9T patent/DK3215133T3/da active
- 2015-11-05 BR BR112017008720A patent/BR112017008720A2/pt not_active Application Discontinuation
- 2015-11-05 AU AU2015342968A patent/AU2015342968B2/en active Active
- 2015-11-05 ES ES20204014T patent/ES2977158T3/es active Active
- 2015-11-05 JP JP2017524451A patent/JP7218089B2/ja active Active
- 2015-11-05 KR KR1020177014830A patent/KR102656139B1/ko active Active
-
2017
- 2017-04-06 IL IL251620A patent/IL251620B/en active IP Right Grant
- 2017-04-06 IL IL251622A patent/IL251622B/en active IP Right Grant
- 2017-05-04 MX MX2021012273A patent/MX2021012273A/es unknown
- 2017-05-04 MX MX2021006698A patent/MX2021006698A/es unknown
-
2021
- 2021-01-27 CY CY20211100063T patent/CY1124418T1/el unknown
- 2021-01-31 IL IL280518A patent/IL280518B/en unknown
- 2021-05-10 JP JP2021080003A patent/JP7827412B2/ja active Active
- 2021-07-27 AU AU2021209202A patent/AU2021209202B2/en active Active
- 2021-07-27 AU AU2021209204A patent/AU2021209204A1/en not_active Abandoned
- 2021-12-02 IL IL288609A patent/IL288609B2/en unknown
-
2022
- 2022-09-01 JP JP2022139392A patent/JP2022173236A/ja active Pending
-
2023
- 2023-07-03 JP JP2023109379A patent/JP2023169893A/ja active Pending
-
2024
- 2024-10-21 US US18/921,868 patent/US20250152561A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537081A5 (https=) | ||
| JP2022173236A5 (https=) | ||
| FI3906918T3 (fi) | Menetelmiä ja koostumuksia, jotka koskevat synteettisiä nanokantajia stabiilissa superkyllästyneessä tilassa olevan rapamysiinin kanssa | |
| JP2017533243A5 (https=) | ||
| JP2021143180A5 (https=) | ||
| Elgindy et al. | Self-assembled nano-architecture liquid crystalline particles as a promising carrier for progesterone transdermal delivery | |
| Mohammadi et al. | Vitamin D3-loaded nanostructured lipid carriers as a potential approach for fortifying food beverages; in vitro and in vivo evaluation | |
| Badie et al. | Novel small self-assembled resveratrol-bearing cubosomes and hexosomes: Preparation, charachterization, and ex vivo permeation | |
| JP5513713B2 (ja) | 非層状分散を生じる組成物 | |
| Yang et al. | The effect of oil type on the aggregation stability of nanostructured lipid carriers | |
| Nakach et al. | Engineering of nano-crystalline drug suspensions: employing a physico-chemistry based stabilizer selection methodology or approach | |
| JP7247164B2 (ja) | 注入可能な油中水型エマルション及びその使用 | |
| Talaat et al. | Lecithin microemulsion lipogels versus conventional gels for skin targeting of terconazole: in vitro, ex vivo, and in vivo investigation | |
| WO2021183781A1 (en) | Methods and compositions related to synthetic nanocarriers | |
| WO2015186040A1 (en) | Stable nanoemulsion composition | |
| Damitz et al. | Kinetically stable propofol emulsions with reduced free drug concentration for intravenous delivery | |
| Baviskar et al. | Modulation of drug release from nanocarriers loaded with a poorly water soluble drug (flurbiprofen) comprising natural waxes | |
| Dash et al. | Development and characterization of paliperidone loaded nanostructured lipid carrier | |
| CA2541009C (fr) | Compositions de particules lipidiques solides monodisperses | |
| US11963936B2 (en) | Method of manufacturing stable emulsions and compositions containing the same | |
| Swidan et al. | Comparative study of solid lipid nanoparticles and nanostructured lipid carriers for in vitro Paclitaxel delivery | |
| Bejrapha et al. | Studies on the role of gelatin as a cryo-and lyo-protectant in the stability of capsicum oleoresin nanocapsules in gelatin matrix | |
| Rahma et al. | The influence of non-ionic surfactant on the physical characteristics of curcumin-loaded nanofiber manufactured by electrospinning method | |
| US20200254046A1 (en) | Pharmaceutical compositions | |
| Anurak et al. | Griseofulvin solid lipid nanoparticles based on microemulsion technique |